Business
Exercise of Options
IXICO plc announced the issuance of 926,686 new ordinary shares following the exercise of share options, with Chief Executive Officer Bram Goorden exercising 926,686 options. These new shares, ranking pari passu with existing ones, will be admitted to trading on the AIM Market of the London Stock Exchange on 24 June 2026, bringing the total issued share capital to 218,974,282 ordinary shares. Following this exercise, Mr. Goorden's holding increased to 2,390,501 ordinary shares, representing approximately 1.1% of the Company's current issued share capital. Disclaimer*
About this update from Ixico Plc
19 June 2026 IXICO plc ("IXICO", the "Company" or the "Group") Exercise of Options IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that it has issued, conditional on admission, 926,686 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options ("Options") under the Company's October 2024 Option Awards (the "2024 Plan"). 926,686 of these Options were exercised by Bram Goorden, Chief Executive Officer and PDMR of the Company. All tax and costs were paid separately by Mr Goorden with no sale of Ordinary Shares required. Following this exercise, Mr Goorden's holding has increased to 2,390,501 Ordinary Shares representing approximately 1.1% of the current Issued Share Capital of the Company. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue and application has been made for the new Ordinary Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). Admission is expected to occur, and dealings in the new Ordinary Shares commence, at 8:00 a.m. on 24 June 2026. Total Voting Rights Following Admission, the Company will have 218,974,282 Ordinary Shares in issue. This figure of 218,974,282 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. Ends For further information please contact: IXICO plc +44 (0) 20 3763 7499 Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) +44 (0) 20 7220 0500 Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) About IXICO www.IXICO.com IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with dru...